Embla Medical hfOCSE:EMBLA -0.57%92 Price-to-Operating-Cash-Flow is 13.45 as of Jun. 24, 2026, which is 49% below its 10-year median of 26.51. GuruFocus rates OCSE:EMBLA with a GF Score™ of 92/100 and a GF Value™ of kr34.32 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 498 Medical Devices & Instruments companies, Embla Medical hf ranks better than 63.25% on this metric.
As of today (2026-06-24), Embla Medical hf's share price is kr25.95.
Embla Medical hf's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.93. Hence, Embla Medical hf's Price-to-Operating-Cash-Flow Ratio for today is 13.45.
The historical rank and industry rank for Embla Medical hf's Price-to-Operating-Cash-Flow or its related term are showing as below:
OCSE:EMBLA'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.79 Med: 26.51 Max: 40.14
Current: 13.45
During the past 13 years, Embla Medical hf's highest Price-to-Operating-Cash-Flow Ratio was 40.14. The lowest was 12.79. And the median was 26.51.
OCSE:EMBLA's Price-to-Operating-Cash-Flow is ranked better than 63.25% of 498
companies
in the Medical Devices & Instruments industry
Industry Median: 16.655
vs OCSE:EMBLA: 13.45
Embla Medical hf's Cash Flow from Operations per share for the
three
months ended in Mar. 2026 was kr0.14.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.93.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Embla Medical hf was -6.20% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 24.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 9.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 6.40% per year.
During the past 13 years, Embla Medical hf's highest 3-Year average Operating Cash Flow per Share Growth Rate was 52.50% per year. The lowest was -12.20% per year. And the median was 7.50% per year.
Embla Medical hf Price-to-Operating-Cash-Flow Related Terms
Embla Medical hf Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf Price-to-Operating-Cash-Flow Chart
OCSE:EMBLA vs ABT, SYK, MDT: Price-to-Operating-Cash-Flow Comparison
For the Medical Devices subindustry, Embla Medical hf's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Price-to-Operating-Cash-Flow falls into.
Embla Medical hf Price-to-Operating-Cash-Flow Calculation
Embla Medical hf's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
25.95
/
1.93
=
13.45
Embla Medical hf's Share Price of today is kr25.95. Embla Medical hf's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 13.45 mean?
Embla Medical hf (OCSE:EMBLA) has a Price-to-Operating-Cash-Flow of 13.45 as of Jun. 24, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Embla Medical hf and its competitors. This is 49% below median its historical median of 26.51. Over the past decade, Embla Medical hf's Price-to-Operating-Cash-Flow has ranged from 12.79 to 40.14. According to the industry distribution chart, Embla Medical hf ranks #183 out of 498 companies in the Medical Devices & Instruments industry, placing it in the top 36.7%.
Is Embla Medical hf's Price-to-Operating-Cash-Flow too high?
Embla Medical hf's current Price-to-Operating-Cash-Flow of 13.45 is 49% below median its 10-year median of 26.51. Over the past 10 years, this metric has ranged from a low of 12.79 to a high of 40.14. The Medical Devices & Instruments industry median Price-to-Operating-Cash-Flow is 16.66. Embla Medical hf's value of 13.45 is 19.2% below this industry median. Based on the distribution chart, Embla Medical hf ranks #183 out of 498 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Price-to-Operating-Cash-Flow compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #183 out of 498 companies for Price-to-Operating-Cash-Flow. This puts Embla Medical hf in the upper half of its industry. The industry median Price-to-Operating-Cash-Flow is 16.66. Embla Medical hf's value of 13.45 is 19.2% below this benchmark. Historically, Embla Medical hf's own Price-to-Operating-Cash-Flow has ranged from 12.79 to 40.14 over the past decade. While the company's 10-year median is 26.51 vs. the industry median of 16.66, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Medical Devices & Instruments company?
The median Price-to-Operating-Cash-Flow among Medical Devices & Instruments companies is 16.66, based on 498 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Price-to-Operating-Cash-Flow of 13.45 is 19.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Operating-Cash-Flow is 16.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Price-to-Operating-Cash-Flow is 13.45, which is 49% below median its own 10-year median of 26.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.32, compared to a current price of kr25.95 — trading 24.4% below its estimated fair value. The current Price-to-Operating-Cash-Flow is 13.45, which is 49% below median its 10-year median of 26.51 and 19.2% below the Medical Devices & Instruments industry median of 16.66. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current Price-to-Operating-Cash-Flow is 13.45 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of kr25.95 is trading 24.4% below its estimated GF Value™ of kr34.32.
GuruFocus considers Embla Medical hf to be Modestly Undervalued.
Key valuation signals for OCSE:EMBLA:
Price-to-Operating-Cash-Flow: 13.45 (49% below median its 10-year median of 26.51)
GF Value™: kr34.32 vs. price of kr25.95 (24.4% below fair value)
Industry Position: 19.2% below the Medical Devices & Instruments median (#183 of 498)
No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OCSE:EMBLA
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:EMBLA has been successfully added to your 
